Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Oct;31(10):1605–1608. doi: 10.1128/aac.31.10.1605

Ceftazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitis.

M C Bach 1, D M Cocchetto 1
PMCID: PMC174999  PMID: 3124734

Abstract

The cases of 28 patients who received ceftazidime as single-agent therapy in prospective clinical trials for biopsy culture-proven osteomyelitis were reviewed. These cases all involved infection caused by gram-negative aerobic bacilli, the most frequent agent (83% of patients) being Pseudomonas aeruginosa. Posttreatment follow-up for patients with acute osteomyelitis was continued for at least 6 months, while follow-up for at least 12 months was done for patients with chronic osteomyelitis. A regimen of 2 g of ceftazidime intravenously every 12 h was used for most patients. The overall cure rates were 77% (acute disease) and 60% (chronic disease). Development of resistance to ceftazidime was not problematic, and the drug was well tolerated. Ceftazidime is effective for serious gram-negative bacillary osteomyelitis, including that due to P. aeruginosa. The twice-daily regimen did not cause major organ toxicity, eliminating the need for concentration monitoring and making it feasible to use the drug for home parenteral therapy.

Full text

PDF
1605

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong G. C., Wise R., Brown R. M., Hancox J. Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. Antimicrob Agents Chemother. 1981 Sep;20(3):356–358. doi: 10.1128/aac.20.3.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. De Bastiani G., Nogarin L., Molinaroli F., Bragantini A., Fostini R. Use of ceftazidime in the treatment of osteomyelitis and osteoarthritis. Int J Clin Pharmacol Ther Toxicol. 1986 Dec;24(12):677–679. [PubMed] [Google Scholar]
  3. Fitzgerald R. H., Jr, Cowan J. D. Puncture wounds of the foot. Orthop Clin North Am. 1975 Oct;6(4):965–972. [PubMed] [Google Scholar]
  4. Gentry L. O., Macko V., Lind R., Heilman A. Ticarcillin plus clavulanic acid (Timentin) therapy for osteomyelitis. Am J Med. 1985 Nov 29;79(5B):116–121. doi: 10.1016/0002-9343(85)90142-1. [DOI] [PubMed] [Google Scholar]
  5. Gentry L. O. Treatment of skin, skin structure, bone, and joint infections with ceftazidime. Am J Med. 1985 Aug 9;79(2A):67–74. doi: 10.1016/0002-9343(85)90264-5. [DOI] [PubMed] [Google Scholar]
  6. Gilbert D. N., Tice A. D., Marsh P. K., Craven P. C., Preheim L. C. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. Am J Med. 1987 Apr 27;82(4A):254–258. [PubMed] [Google Scholar]
  7. Greenberg R. N., Tice A. D., Marsh P. K., Craven P. C., Reilly P. M., Bollinger M., Weinandt W. J. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med. 1987 Apr 27;82(4A):266–269. [PubMed] [Google Scholar]
  8. MacGregor R. R., Gentry L. O. Imipenem/cilastatin in the treatment of osteomyelitis. Am J Med. 1985 Jun 7;78(6A):100–103. doi: 10.1016/0002-9343(85)90109-3. [DOI] [PubMed] [Google Scholar]
  9. Mackowiak P. A., Jones S. R., Smith J. W. Diagnostic value of sinus-tract cultures in chronic osteomyelitis. JAMA. 1978 Jun 30;239(26):2772–2775. doi: 10.1001/jama.239.26.2772. [DOI] [PubMed] [Google Scholar]
  10. Mackowiak P. A., Smith J. W. Polymicrobial infections in osteomyelitis. Rev Infect Dis. 1983 Jan-Feb;5(1):167–168. doi: 10.1093/clinids/5.1.167. [DOI] [PubMed] [Google Scholar]
  11. Miller E. H., Semian D. W. Gram-negative osteomyelitis following puncture wounds of the foot. J Bone Joint Surg Am. 1975 Jun;57(4):535–537. [PubMed] [Google Scholar]
  12. Norrby S. R., Burman L. A., Linderholm H., Trollfors B. Ceftazidime: pharmacokinetics in patients and effects on the renal function. J Antimicrob Chemother. 1982 Sep;10(3):199–206. doi: 10.1093/jac/10.3.199. [DOI] [PubMed] [Google Scholar]
  13. O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980 May;17(5):876–883. doi: 10.1128/aac.17.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pichichero M. E., Friesen H. A. Polymicrobial osteomyelitis: report of three cases and review of the literature. Rev Infect Dis. 1982 Jan-Feb;4(1):86–96. doi: 10.1093/clinids/4.1.86. [DOI] [PubMed] [Google Scholar]
  15. Rotimi V. O., Turk D. C. Transferable multiple antibiotic resistance in Haemophilus influenzae. J Antimicrob Chemother. 1981 Sep;8(3):187–192. doi: 10.1093/jac/8.3.187. [DOI] [PubMed] [Google Scholar]
  16. Scully B. E., Neu H. C. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria. Arch Intern Med. 1984 Jan;144(1):57–62. doi: 10.1001/archinte.144.1.57. [DOI] [PubMed] [Google Scholar]
  17. Sheftel T. G., Mader J. T. Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli. Antimicrob Agents Chemother. 1986 Jan;29(1):112–115. doi: 10.1128/aac.29.1.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sommers D. K., Walters L., Van Wyk M., Harding S. M., Paton A. M., Ayrton J. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother. 1983 Jun;23(6):892–896. doi: 10.1128/aac.23.6.892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tanphaichitra D., Bussayanond A., Christensen O. The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever. J Antimicrob Chemother. 1981 Jul;8(1):23–28. doi: 10.1093/jac/8.1.23. [DOI] [PubMed] [Google Scholar]
  20. Verbist L., Verhaegen J. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae. Antimicrob Agents Chemother. 1980 May;17(5):807–812. doi: 10.1128/aac.17.5.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Walstad R. A., Hellum K. B., Blika S., Dale L. G., Fredriksen T., Myhre K. I., Spencer G. R. Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):275–282. doi: 10.1093/jac/12.suppl_a.275. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES